EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay Pharmaceuticals, Inc. (AMEX & TSX: NBY, www.novabaypharma.com), a clinical stage biopharmaceutical company developing products for the treatment or prevention of a wide range of bacterial, fungal, and viral infections, reports its financial results for the first quarter ended March 31, 2008. At March 31, 2008, NovaBay had approximately $20.2 million in cash, cash equivalents, and short-term investments. Additional details on the financial results are presented later in this release.
